Antifungal and antibacterial peptides

Details Antifungal and antibacterial peptides Antifungal and antibacterial peptides

1997-12-18

2003-03-11

Davenport, Avis M. (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

15 to 23 amino acid residues in defined sequence

C530S327000, C514S013800, C514S014800

Reexamination Certificate

active

06531573

ABSTRACT:

BACKGROUND OF THE INVENTION
The invention relates to antifingal and antibacterial peptides.
Bacterial and fungal infections are prevalent and, in some cases, life-threatening conditions that affect otherwise healthy patients. Bacterial and fungal infections are especially dangerous for immuno-compromised patients. For these patients, systemic fungal infections can lead to death, since there are few safe and effective antifungal pharmaceuticals for intravenous use. Similarly, infections with various bacterial species can cause sever disease states and even death.
Although several antifungal agents (e.g., clotrimazole, miconazole, ketoconazole, and nystatin) and antibacterial agents (e.g., penicillin, streptomycin, tetracycline, and chlorhexidine) are currently available, these agents are not completely effective. These agents can also lead to drug resistant organisms and can produce adverse side effects. In addition, many are not appropriate for oral or systemic administration.
SUMMARY OF THE INVENTION
The invention features substantially pure peptides containing between 13 and 20 amino acids, inclusive; the peptides have the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent; and R23 is Gly or is absent; where Gln cannot simultaneously occupy positions R5, R6, R12, and R13 of the amino acid sequence of a peptide.
In preferred peptides, at least one of R7, R8, R11, and R15 is Phe; R9 is Lys; R11 is His; or at least one of R7, R8, and R15 is Tyr; or any combination of these substitutions is present in the peptide. In other preferred peptides, R1, R2, and R3 are absent; alternatively, R22 and R23 are absent; R20, R21, R22, and R23 are absent; or R18, R19, R20, R21, R22, and R23 are absent.
The peptides may have substituents bonded to either terminus of the peptide. For example, the peptide may have an acetyl or a carbamyl addition at the N-terminus, and/or an amide addition at the C-terminus.
Preferred peptides contain 13-16 amino acids, and more preferably contain 13-14 amino acids. The invention further features pharmaceutical compositions including the peptides of the invention.
The peptides of the present invention have potent antibacterial and antifungal properties, and the invention also features methods for treating bacterial and fungal infections using these peptides.
Other features and advantages of the invention will be apparent from the following description and from the claims.


REFERENCES:
patent: 4705777 (1987-11-01), Lehrer et al.
patent: 4725576 (1988-02-01), Pollock et al.
patent: 5032574 (1991-07-01), Wilde et al.
patent: 5126257 (1992-06-01), Gabay et al.
patent: 5221732 (1993-06-01), Chen et al.
patent: 5225399 (1993-07-01), Zasloff et al.
patent: 5239059 (1993-08-01), Zasloff et al.
patent: 5304633 (1994-04-01), Tomita et al.
patent: 5324716 (1994-06-01), Selested et al.
patent: 5486503 (1996-01-01), Oppenheim et al.
patent: 5631228 (1997-05-01), Oppenheim et al.
patent: 5646119 (1997-07-01), Oppenheim et al.
patent: 5672351 (1997-09-01), Chikindas et al.
patent: 5696078 (1997-12-01), Oppenheim et al.
patent: 66-234653 (1994-08-01), None
patent: 6-287146 (1994-10-01), None
patent: 94/21672 (1994-09-01), None
Richardson et al., “The Influence of Histatin-5 Fragments on the Mineralization of Hydroxyapatite”Arch. Oral Biol.38:997-1002, 1993.
Dickinson et al., “Human Submandibular Gland Statherin and Basic Histidine-Rich Peptide and Encoded by Highly Abundant mRNA's Derived from a Common Ancestral Sequence”, Biochemical and Biophysical Research Communications, 149:784-790 (1987).
Docherty and Pollock, “Inactivation of Herpes Simplex Virus Types 1 and 2 by Synthetic Histidine Peptides”, Antimicrobial Agents and Chemotherapy, 31:1562-1566 (1987).
Edgerton et al., “Surface-modified poly(methyl methacrylate) enhances adsorption and retains anticandidal activities of salivary histatin 5”, Journal of Biomedical Material 29:1277-1286 (1995).
Iwaki et al., “Oral Immunization with RecombinantStreptococcus IactisCarrying the Streptococcus mutans Surface Protein Antigen Gene”, Infect. Immun., 58:2929-2934 (Sep. 1990).
Kuramitsu and Long, “Plasmid-Mediated Transformation of Streptococcus mutans”, Infect. Immun., 36:435-436 (1982).
Macrina et al., “Chimeric Streptococcal Plasmids and Their Use as Molecular Cloning Vehicles in Streptococcus sanguis (Challis)”, J. Bacteriol., 143:1425-1435 (1980).
Minaguchi et al., “Genetics of Human Salivary Proteins”, Journal of Dental Research, 68:2-15 (1989).
Murakami et al., “Inhibitory Effects of Synthetic Histidine-Rich Peptides on Haemagglutination by Bacteroides Gingivalis 381”, Arch. Oral Biol., 35:775-777 (1990).
Nishikata et al., “Salivary Histatin as a Inhibitor of a Protease Produced by the Oral Bacterium Bacteroides ginvalis”, 174:625-630 (1991).
Oppenheim et al., “Histatins, a Novel Family of Histidine-Rich Proteins in Human Paretoid Secretion”, J. Biol. Chem., 263:7472-7477 (1988).
Oppenheim et al., “Isolation and Characterization of a Major Histatin From Macaque Parotid Secretion”, FASEB J., 4:A2165 (Apr. 1990) (Abstract only, #2731).
Raj. P.A. et al., “Salivary Histatin 5: Dependence of Sequence, Chain Length, and Helical Confirmation for Candidacidal Activity”, J Biol. Chem., 265:3898-3905 (1990).
Sabatini et al., “Tissue Distribution of RNAs for Cystatins, Histatins, Statherin, and Proline-rich Salivary Proteins in Humans and Macaques”, Journal of Dental Research, 68:1138-1145 (1989).
Sabatini et al., “Histatins, A Family of Salivary Histidine-Rich Proteins, are Encoded by at Least Two LOCI (HIS1 and HIS2)”, Biochemical and Biophysical Research Communications, 160:495-502 (1989).
Sabatini et al., “Tissue Distribution of RNAs for Salivary-type Proteins in Humans and Monkeys: proline-rich proteins, statherin, cystatins, and histidine-rich proteins”, American Journal of Human Genetics, 43(3, Supplement):A199, Absract 0795 (1988).
Santarpia et al., “A Comparison of the Inhibition of Blastospore Viability and Germ-Tube Development in Candida albicans by Histidine Peptides and Ketoconazole”, Arch. Oral. Biol., 33:567-573 (1988).
Santarpia III, et al., “Preliminary Findings for In Vivo Efficacy of Salivary Histidine-Rich Polypeptidse”, J. Dent. Res., 69:173 (1990) (Abstract only, #515).
Sugiyama, et al., “Rapid Purification and Characterization of Histatins (Histidine-Rich Polypeptides) from Human Whole Saliva”, Archives of Oral Biology, 35:415-419 (1990).
Svanberg et al., “Oral Implantation in Humans of Streptococcus mutans Strains with Different Degrees of Hydrophobicity”, Infect. Immun., 43:817-821 (1984).
Troxler et al., “Structural Relationship Between Human Salivary Histatins”, J. Dent. Res., 69:2-6 (1990).
vanderSpek et al., “Molecular Cloning of Human Submandibular Histatins”, Archives of Oral Biology, 35:137-143 (1990).
vanderSpek et al., “Localization of the Genes for Histatins to Human chromosome 4q13 and Tissue Distribution of the mRNAs”, American Journal of Human Genetics, 45:381-387 (1989).
Xu et al., “Structure/Function analysis of Anti-Candida Activities of Histatin 1”, J. Dent. Res., 68:973 (1989) (Abstract only, #853).
Xu et al., “Anticandidal Activity of Major Human Salivary Histatins”, 59:2549-2554 (1991).
Xu et al., “Primary Structure and

Affiliated with

Also associated with

Rating

Antifungal and antibacterial peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antifungal and antibacterial peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antifungal and antibacterial peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3019424